September 1st 2023.
Zydus Lifesciences Limited has exciting news to share! On Friday, the company received final approval from the United States Food and Drug Administration for Erythromycin Tablets USP, 250mg and 500mg.
Erythromycin tablets, USP are an antibacterial product used to treat and prevent infections in many parts of the body, including the respiratory tract, skin, diphtheria, and Legionnaire's disease. The drug will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad.
The tablets had annual sales of USD 23 million in the United States. This marks the 379th approval and the 444th ANDA filing since the commencement of the process in FY 2003-04.
On Friday, Zydus Lifesciences Limited shares were trading at Rs 614, down 1.89 percent. This news is a great step forward for the company and is sure to have a positive effect on their stock prices in the coming weeks.
Overall, Zydus Lifesciences Limited is continuing to make strides in the medical field. With this new approval, they can now offer more efficient and effective treatments to those in need.
[This article has been trending online recently and has been generated with AI. Your feed is customized.]
0 Comments